Your browser doesn't support javascript.
loading
Concurrent gliomas in patients with multiple sclerosis.
Sahm, Katharina; Kessler, Tobias; Eisele, Philipp; Ratliff, Miriam; Sperk, Elena; König, Laila; Breckwoldt, Michael O; Seliger, Corinna; Mildenberger, Iris; Schrimpf, Daniel; Herold-Mende, Christel; Zeiner, Pia S; Tabatabai, Ghazaleh; Meuth, Sven G; Capper, David; Bendszus, Martin; von Deimling, Andreas; Wick, Wolfgang; Sahm, Felix; Platten, Michael.
Affiliation
  • Sahm K; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg, Mannheim, Germany. k.sahm@dkfz.de.
  • Kessler T; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. k.sahm@dkfz.de.
  • Eisele P; Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ratliff M; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Sperk E; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg, Mannheim, Germany.
  • König L; Department of Neurosurgery, Medical Faculty Mannheim, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg, Mannheim, Germany.
  • Breckwoldt MO; Department of Radiation Oncology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Seliger C; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
  • Mildenberger I; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schrimpf D; Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Herold-Mende C; Department of Neurology and Neurooncology Program, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Zeiner PS; Wilhelm Sander-NeuroOncology Unit and Department of Neurology, Regensburg University Hospital, Regensburg, Germany.
  • Tabatabai G; Department of Neurology, Medical Faculty Mannheim, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg, Mannheim, Germany.
  • Meuth SG; Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Capper D; Department of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Bendszus M; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • von Deimling A; Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Wick W; Dr Senckenberg Institute of Neurooncology, University of Frankfurt, Frankfurt, Germany.
  • Sahm F; Department of Neurology & Interdisciplinary Neurooncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Platten M; Department of Neurology, Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Commun Med (Lond) ; 3(1): 186, 2023 Dec 18.
Article in En | MEDLINE | ID: mdl-38110626
Brain tumors such as gliomas can evade attacks by the immune system. In contrast, some diseases of the central nervous system such as multiple sclerosis (MS) are caused by an overactive immune system. Our study looks at a cohort of rare patients with both malignant glioma and concurrent MS and examines how each disease and their treatments affect each other. Our data suggest that even in patients with known MS, if medical imaging findings are unusual, a concurrent brain tumor should be excluded at an early stage. Radiotherapy, as is the standard of care for malignant brain tumors, may worsen the inflammatory disease activity in MS patients, which may be associated with certain genetic risk factors. Our findings may help to inform treatment of patients with brain tumors and MS.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Commun Med (Lond) Year: 2023 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Commun Med (Lond) Year: 2023 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido